Dr. med. Martin Voß


Dr. med. Martin Voß

Facharzt für Neurologie


Ärztlicher Direktor


Sehen Sie sich meine Sprechstunden an und vereinbaren Sie einen Termin.

Kontakt und Auskunft


Direktkontakt für Zuweiser

Sie müssen JavaScript aktivieren, um diese Information abrufen zu können.

DocCheck Authentifizierung

Bitte authentifizieren Sie sich über


  • Neurologie / FA Neurologie / 12 Monate / LÄK Hessen / /


Höhepunkte der beruflichen Laufbahn

  • 2015 Oberarzt des Dr. Senckenbergischen Instituts für Neuroonkologie, Johann Wolfgang Goethe Universität, Frankfurt am Main
  • 2018 Ärztlicher Koordinator des Neuroonkologischen Zentrums, Johann Wolfgang Goethe-Universität, Frankfurt am Main

Weiterbildung Zusatzbezeichnung

  • Weiterbildungsbefugnis Neurologie
  • Zusatzbezeichnung Intensivmedizin
  • Zusatzbezeichnung Medikamentöse Tumortherapie
  • Zusatzbezeichnung Palliativmedizin


  • Facharzt für Neurologie

Mitgliedschaften in medizinischen Fachgesellschaften

  • Deutsche Gesellschaft für Neurologie
  • Deutsche Krebsgesellschaft

Weitere Qualifikation

  • A-Diplom Chinesische Akkupunktur

Forschung & Lehre

Wissenschaftliche Interessen

  • Neurologische Rehabilitation

Weitere Publikationen

  • The role of the lymphatic system and its specific growth factor vascular endothelial growth factor C for lymphogenic metastasis in prostate cancer.
  • Complications and side effects of low dose rate brachytherapy for the treatment of prostate cancer: Data on a 13 year follow-up study from Mannheim.
  • Serum Vascular Endothelial Growth Factor C Level in Patients with Prostate Cancer and Benign Prostatic Hyperplasia.
  • The lymphatic system and its specific growth factor vascular endothelial growth factor C in kidney tissue and in renal cell carcinoma.
  • Neuroendocrine tumor cells in prostate cancer: evaluation of the neurosecretory products serotonin, bombesin, and gastrin - impact on angiogenesis and clinical follow-up.
  • Die 50 wichtigsten Fälle Neurologie
  • Omega 3 Fatty Acids: Novel Neurotherapeutic Targets for Cognitive Dysfunction in Mood Disorders and Schizophrenia?
  • Omega-3 fatty acids: repurposing opportunities for cognition and biobehavioral disturbances in MCI and Dementia
  • Treatment of refractory and super-refractory status epilepticus with brivaracetam: A cohort study from two German university hospitals.
  • Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine.
  • Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease.
  • New MR perfusion features in primary central nervous system lymphomas: pattern and prognostic impact.
  • Doxycycline Impairs Mitochondrial Function and Protects Human Glioma Cells from Hypoxia-Induced Cell Death: Implications of Using Tet-Inducible Systems.
  • Contrast enhancing spots as a new pattern of late onset pseudoprogression in glioma patients.
  • Adrenal Insufficiency in Patients with Corticosteroid-Refractory Cerebral Radiation Necrosis Treated with Bevacizumab.
  • Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients.
  • AMPK activation protects astrocytes from hypoxia‑induced cell death.
  • Glioma patients in outpatient care-optimization of psychosocial care in neuro-oncological patients (GLIOPT): Protocol for a cluster randomized controlled trial.
  • ERGO2: A Prospective, Randomized Trial of Calorie-Restricted Ketogenic Diet and Fasting in Addition to Reirradiation for Malignant Glioma.
  • Rescue of 2-Deoxyglucose Side Effects by Ketogenic Diet.
  • Therapeutic Options for Patients with Refractory Status Epilepticus in Palliative Settings or with a Limitation of Life-Sustaining Therapies: A Systematic Review.
  • Treatment of status epilepticus with zonisamide: A multicenter cohort study of 34 patients and review of literature.
  • Benefits of glioma resection in the corpus callosum.
  • Maintenance of Energy Homeostasis during Calorically Restricted Ketogenic Diet and Fasting-MR-Spectroscopic Insights from the ERGO2 Trial.
  • Therapie-Handbuch - Onkologie und Hämatologie
  • Neurotoxicity of subarachnoid Gd-based contrast agent accumulation: a potential complication of intraoperative MRI?
  • Single-shot bevacizumab for cerebral radiation injury.
  • Direct oral anticoagulants vs. low-molecular-weight heparin for pulmonary embolism in patients with glioblastoma.
  • Glioma patients in outpatient care-optimization of psychosocial care in neuro-oncological patients (GLIOPT): Protocol for a cluster randomized controlled trial.
  • Chemotherapy and diffuse low-grade gliomas: a survey within the European Low-Grade Glioma Network.
  • Dexamethasone Treatment Limits Efficacy of Radiation, but Does Not Interfere With Glioma Cell Death Induced by Tumor Treating Fields.
  • Concurrent CNS tumors and multiple sclerosis: retrospective single-center cohort study and lessons for the clinical management
  • Development and external validation of a clinical prediction model for survival in patients with IDH wild-type glioblastoma.
  • Therapeutic Anticoagulation Impacts MR Morphologic Recurrence Patterns in Glioblastoma-A Matched-Pair Analysis.
  • Short-term fasting in glioma patients: analysis of diet diaries and metabolic parameters of the ERGO2 trial.
  • Immune Checkpoint Inhibitor-Induced Cerebral Pseudoprogression: Patterns and Categorization. Front Immunol.
  • Sex-Dependent Analysis of Temozolomide-Induced Myelosuppression and Effects on Survival in a Large Real-life Cohort of Glioma Patients.
  • Neurocognitive Outcome and Seizure Freedom After Awake Surgery of Gliomas.
  • Molecular matched targeted therapies for primary brain tumors-a single center retrospective analysis.
  • High end-of-life incidence of seizures and status epilepticus in patients with primary and secondary brain tumors.
  • Outcome and characteristics of patients with adult grade 4 diffuse gliomas changing sites of treatment

Seite teilen: